Fierce Pharma June 29, 2022
Fujifilm isn’t slowing down on its expansion roll. Just a few months after it bought Shenandoah Biotechnology for an undisclosed sum, the Japanese conglomerate has unveiled a $1.6 billion investment to expand the cell culture manufacturing services of Fujifilm Diosynth Biotechnologies, a CDMO subsidiary.
The investment will benefit its sites in Hillerød, Denmark, and Texas, and create approximately 450 jobs.
In Denmark, Fujifilm Diosynth will expand its capacity to support large-scale batch production through the addition of eight 20,000-liter bioreactors and two downstream processing streams, making it largest end-to-end CDMO in Europe. Once the expansion is complete, the site will feature twenty 20,000-liter bioreactions for drug substance production, plus drug product and finished good services.
The...
Today's Sponsors
Today's Sponsor